COMP <GO>
DOYU vs HCAT // REVENUE GROWTH (YOY)
DouYu International Holdings Limited ADS (NASDAQ) VS. Health Catalyst Inc (NASDAQ) • 15-METRIC TALLY: DOYU 3
— HCAT 5
▲ REVENUE GROWTH (YOY) LEADER: HCAT
LAST: $3.65 (-0.55%) • MKT CAP: $110.2M
revenue-growth
-6.70%
LAST: $1.79 (-0.56%) • MKT CAP: $134.7M
revenue-growth
1.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DOYU VS. HCAT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DOYU | HCAT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 12.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.60% | -35.00% | +36.60 | DOYU | /roic <GO> |
| EV/EBITDA & P/E Valuation | 77.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.82% | -0.18% | -6.64 | HCAT | /fcf-yield <GO> |
| Operating Margin | 0.10% | -51.70% | +51.80 | DOYU | /operating-margins <GO> |
| Net Profit Margin | — | -57.20% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -6.70% | 1.50% | -8.20 | HCAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.50 | 0.20 | +0.30 | DOYU | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 4/9 | -3.00 | HCAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.6 | 46.8 | -12.16 | HCAT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $110.2M | $134.7M | -$24.6M | HCAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DOYU REV | HCAT REV | DOYU GROSS % | HCAT GROSS % | DOYU FCF | HCAT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $546.1M | $311.1M | 12.8% | — | -$7.5M | -$237.0K |
| FY 2024 | $585.1M | $306.6M | 7.6% | — | -$32.8M | $12.9M |
| FY 2023 | $778.9M | $295.9M | — | — | -$6.7M | -$33.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DOYU // BETA —
HCAT // BETA —